Current Period Performance Forecast The company anticipates a significant shift from profit to loss in the first half of 2025, with net profit attributable to shareholders projected to be a substantial loss compared to the prior year's profit Key Financial Performance Indicators | Item | Current Period | Prior Year Period | | :--- | :--- | :--- | | Net Profit Attributable to Shareholders | Loss: 28.00 million - 20.00 million yuan | Profit: 0.5535 million yuan | | Net Profit After Non-Recurring Items | Loss: 26.00 million - 19.00 million yuan | Profit: 0.1691 million yuan | | Basic Earnings Per Share | Loss: 0.0333 - 0.0238 yuan/share | Profit: 0.0007 yuan/share | Pre-Audit Status of Performance Forecast The performance forecast data has not been pre-audited by a certified public accountant and represents preliminary estimates by the company's finance department - This performance forecast has not been pre-audited by a certified public accountant4 Explanation of Performance Change The H1 2025 loss is primarily due to declining profitability in core dental medical services and reduced investment income from the associated company, Fushun Bank - Core business challenges include increased market competition, rising customer acquisition costs, and declining average transaction value in dental medical services, leading to reduced profitability5 - Decreased investment income from the associated company, Fushun Bank, due to a decline in the valuation of its financial product investments, is another significant factor contributing to the loss5 Other Relevant Information The company states that the forecast data is preliminary, with final financial figures subject to the official H1 2025 semi-annual report, and advises investors to be aware of investment risks - The forecast data is preliminary, and the definitive financial figures will be based on the company's officially disclosed 2025 semi-annual report6 - The company will timely disclose information as required and reminds investors to be mindful of investment risks7
皓宸医疗(002622) - 2025 Q2 - 季度业绩预告